Epstein-Barr Virus Infection, B-cell Dysfunction and Other Risk Factors Converge in Gut-associated Lymphoid Tissue to Drive the Immunopathogenesis of Multiple Sclerosis: A hypothesis
Overview
Affiliations
Multiple sclerosis is associated with Epstein-Barr virus (EBV) infection, B-cell dysfunction, gut dysbiosis, and environmental and genetic risk factors, including female sex. A disease model incorporating all these factors remains elusive. Here, we hypothesise that EBV-infected memory B cells (MBCs) migrate to gut-associated lymphoid tissue (GALT) through EBV-induced expression of LPAM-1, where they are subsequently activated by gut microbes and/or their products resulting in EBV reactivation and compartmentalised anti-EBV immune responses. These responses involve marginal zone (MZ) B cells that activate CD4 T-cell responses, via HLA-DRB1, which promote downstream B-cell differentiation towards CD11c/T-bet MBCs, as well as conventional MBCs. Intrinsic expression of low-affinity B-cell receptors (BCRs) by MZ B cells and CD11c/T-bet MBCs promotes polyreactive BCR/antibody responses against EBV proteins (e.g. EBNA-1) that cross-react with central nervous system (CNS) autoantigens (e.g. GlialCAM). EBV protein/autoantigen-specific CD11c/T-bet MBCs migrate to the meningeal immune system and CNS, facilitated by their expression of CXCR3, and induce cytotoxic CD8 T-cell responses against CNS autoantigens amplified by BAFF, released from EBV-infected MBCs. An increased abundance of circulating IgA MBCs, observed in MS patients, might also reflect GALT-derived immune responses, including disease-enhancing IgA antibody responses against EBV and gut microbiota-specific regulatory IgA plasma cells. Female sex increases MZ B-cell and CD11c/T-bet MBC activity while environmental risk factors affect gut dysbiosis. Thus, EBV infection, B-cell dysfunction and other risk factors converge in GALT to generate aberrant B-cell responses that drive pathogenic T-cell responses in the CNS.
The Role of CXCR3 in Nervous System-Related Diseases.
Wang F, Guo B, Jia Z, Jing Z, Wang Q, Li M Mediators Inflamm. 2024; 2024:8347647.
PMID: 39429695 PMC: 11488998. DOI: 10.1155/2024/8347647.
Kawakami N, Wekerle H Neurotherapeutics. 2024; 21(6):e00442.
PMID: 39237437 PMC: 11585894. DOI: 10.1016/j.neurot.2024.e00442.
The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis.
Saadh M, Ahmed H, Alani Z, Al Zuhairi R, Almarhoon Z, Ahmad H Neuromolecular Med. 2024; 26(1):14.
PMID: 38630350 DOI: 10.1007/s12017-024-08783-4.
Akesson J, Hojjati S, Hellberg S, Raffetseder J, Khademi M, Rynkowski R Nat Commun. 2023; 14(1):6903.
PMID: 37903821 PMC: 10616092. DOI: 10.1038/s41467-023-42682-9.
Plasma IgG aggregates as biomarkers for multiple sclerosis.
Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G Clin Immunol. 2023; 256:109801.
PMID: 37816415 PMC: 11830478. DOI: 10.1016/j.clim.2023.109801.